Imaging and targeted agents in gastrointestinal cancers: Overview on perfusion- and diffusion-weighted magnetic resonance imaging and angiogenesis inhibitors

Targeted Oncology

Volumn 3, Issue 2, 2008, Pages 101-110

  Vandecaveye, Vincent ^a   De Keyzer, Frederik ^a   Dymarkowski, Steven ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Angiogenesis inhibitors; Diffusion weighted MRI; Dynamic contrast enhanced MRI; Treatment follow up; Tumour

Indexed keywords

EID: 42449113694     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-008-0076-7     Document Type: Article

References (56)

1. Laking GR, West C, Buckley DL, Matthews J, Price PM (2005) Imaging vascular physiology to monitor cancer treatment. Crit Rev Oncol Hematol 58:95-113
2. Duda DG, Jain RK, Willet CG (2007) Antiangiogenics: the potential role of integrating this novel Treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033-4042
3. Therasse P (2002) Measuring the clinical response. What does it mean? Eur J Cancer 38:1817-1923
4. Weber WA (2005) Use of PET for monitoring cancer therapy and for predicting outcome. J Nucl Med 46:983-995
5. Akhurst T, Kates TJ, Mazumdar M et al (2005) Recent chemotherapy reduces the sensitivity of [18F] fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23:8713-8716
6. Koh DM, Collins DJ (2007) Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR 188:1622-1635
7. Margolis DJ, Hoffman JM, Herfkens RJ, Jeffrey RB, Quon A, Gambhir SS (2007) Molecular imaging techniques in body imaging. Radiology 245:333-356
8. Seierstad T, Røe K, Olsen DR (2007) Noninvasive monitoring of radiation-induced treatment response using proton magnetic resonance spectroscopy and diffusion-weighted magnetic resonance imaging in a colorectal tumor model. Radiother Oncol 85:187-194
9. Sorensen AG (2006) Magnetic resonance as a cancer imaging biomarker. J Clin Oncol 20:3274-3281
10. Padhani AR (2003) MRI for assessing antivascular cancer treatments. Br J Radiol 76:S60-S80
11. Herneth AM, Guccione S, Bednarski M (2003) Apparent diffusion coefficient: a quantitative parameter for in vivo tumor characterization. Eur J Radiol 45:208-213
12. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
13. Hashizume H, Baluk P, Morikawa S et al (2000) Openings between defective endothelial cell explains tumor vessel leakiness. Am J Pathol 156:1363-1680
14. Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM (1999) Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 237:97-132
15. Kvistad K, Rydland J, Vainio J et al (2000) Breast lesions: evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging. Radiology 216:545-553
16. Tofts PS, Buckley DL, Evelhoch JL (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10:223-232
17. Port RE, Knopp MV, Brix G (2001) Dynamic contrast-enhanced MRI using Gd-DTPA: interindividual variability of the arterial input function and consequences for the assessment of kinetics in tumors. Magn Reson Med 45:1030-1038
18. Tofts PS, Kermode AG (1991) Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 17:357-367
19. Leach MO, Brindle KM, Evelhoch JL et al (2003) Assessment of anti-angiogenic and anti-vascular therapeutics using magnetic resonance imaging: recommendations for appropriate methodology for clinical trials. Br J Radiol 76:S87-S91
20. Brix G, Bahner ML, Hoffmann U, Horvath A, Shreiber W (1999) Regional blood flow, capillary permeability, and compartmental volumes: measurements with dynamic CT-initial experience. Radiology 210:269-276
21. Leach MO, Brindle KM, Evelhoch JL et al (2005) The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations. Br J Cancer 92:1599-1610
22. O'Connor JP, Jackson A, Parker GJ, Jayson GC (2007) DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 29:189-195
23. Hawighorst H, Knapstein PG, Weikel W et al (1997) Angiogenesis of uterine cervical carcinoma: characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement. Cancer Res 57:4777-4786
24. Su MY, Cheung YC, Fruehauf JP et al (2003) Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging 18:467-477
25. Knopp MV, Weiss E, Sinn HP et al (1999) Pathophysiological basis of contrast enhancement in breast tumors. J Magn Reson Imaging 10:260-266
26. Pham CD, Roberts TP, Van Bruggen N et al (1998) Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor. Cancer invest 16:225-230
27. Morgan B, Thomas AL, Drecs J et al (2003) Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 21:3955-3964
28. DeVries AF, Kremser C, Hein PA et al (2003) Tumor microcirculation and diffusion predict outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 15:958-965
29. Mayr NA, Yuh WT, Arnholt JC et al (2001) Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer. J Magn Reson Imaging 12:1027-1033
30. van Laarhoven HW, Klomp DW, Rijpkema M et al (2007) Prediction of chemotherapeutic response of colorectal liver metastases with dynamic gadolinium-DTPA-enhanced MRI and localized 19F MRS pharmacokinetic studies of 5-fluorouracil. NMR Biomed 20:128-140
31. Thoeny HC, De Keyzer F, Vandecaveye V et al (2005) Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237:492-499
32. Jenkinson MD, Plessis DG, Walker C, Smith TS (2007) Advanced MRI in the management of adult gliomas. Br J Neurosurg 21:550-561
33. Cha S, Lu S, Johnson G, Knopp EA (2000) Dynamic susceptibility contrast MR imaging: correlation of signal intensity changes with cerebral blood volume measurements. J Magn Reson Imaging 11:114-119
34. Le Bihan D, Breton E, Lallemand D, Aubin ML et al (1988) Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology 168:497-505
35. Ross BD, Moffat A, Lawrence TS et al (2003) Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2:581-587
36. Melhem ER, Itoh R, Jones L et al (2000) Diffusion tensor imaging of the brain: effect of diffusion weighting on trace and anisotropy measurements. Am J Neuroradiol 21:1813-1820
37. Chenevert TL, Meyer CR, MOffat BA et al (2002) Diffusion MRI: a new strategy for assessment of cancer therapeutic efficacy. Mol Imaging 1:336-343
38. Roth Y, Tichler T, Kostenich G et al (2004) High-b-value diffusion-weighted MR-imaging for pre-treatment prediction and early monitoring of tumor response to therapy in mice. Radiology 232:685-92
39. Low RN, Gurney J (2007) Diffusion-weighted MRI (DWI) in the oncology patient: value of breathhold DWI compared to unenhanced and gadolinium-enhanced MRI. J Magn Reson Imaging 25:848-858
40. Vandecaveye V, De Keyzer F, Nuyts S et al (2007) Detection of head and neck squamous cell carcinoma with diffusion weighted MRI after (chemo)radiotherapy: correlation between radiologic and histopathologic findings. Int J Radiat Oncol Biol Phys 67:960-971
41. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275-282
42. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM (2007) Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 11:1112-1119
43. Willett CG, Boucher Y, di Tomaso E et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10:145-147
44. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 7:58-62
45. Jayson GC, Zweit J, Jackson A et al (2002) Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 94:1484-1493
46. Thoeny HC, De Keyzer F, Chen F et al (2005) Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology 234:756-764
47. Vestergaard-Poulsen P, Hansen B, Ostergaard L, Jakobsen R (2007) Microstructural changes in ischemic cortical gray matter predicted by a model of diffusion-weighted MRI. J Magn Reson Imaging 26:529-540
48. Magnon C, Galaup A, Rouffiac V et al (2007) Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration. Gen Ther 14:108-117
49. Willett CG, Kozin SV, Duda DG et al (2006) Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. Semin Oncol 33:S35-S40
50. Moore HG, Akhurst, Larson SM, Minsky BD, Mazumdar M, Guillem JG (2003) Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice. J Am Coll Surg 197:22-28
51. Engehart R, Kimmig B, Strauss LG et al (1992) Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score. Stralenther Onkol 168:203-212
52. Broxterman HJ, Lankelma J, Hoekman K (2004) Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist Updat 6:111-127
53. O'Neill B, Brown G, Heald RJ, Cunningham D, Tait D (2007) Non-operative treatment after neoadjuvant chemoradiotherapy for rectal cancer. Lancet Oncol 8:625-633
54. Koh DM, Scurr E, Collins D et al (2007) Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. Am J Roentgenol 188:1001-1008
55. Duda DG, Jain RK, Willett CG (2007) Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers. J Clin Oncol 25:4033-4042
56. Tsushima Y, Takano A, Taketomi-Takahashi A, Endo K (2007) Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images. Acad Radiol 14:643-650